Bicycle Therapeutics plc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M | $7.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $240.3M | $173.0M | $156.5M | $81.6M | $44.9M | $33.1M | $25.5M | $20.8M |
| SG&A Expense | $79.4M | $72.2M | $60.4M | $49.5M | $32.4M | $29.2M | $14.6M | $8.1M |
| Operating Income | $-247.1M | $-209.9M | $-189.9M | $-116.7M | $-65.6M | $-52.0M | $-26.3M | $-21.7M |
| Operating Margin | -340.4% | -595.0% | -704.1% | -806.6% | -561.0% | -500.1% | -190.6% | -304.7% |
| Interest Expense | — | — | $3.3M | $3.3M | $3.0M | $457.0K | — | — |
| Pretax Income | $-218.8M | $-173.8M | $-179.2M | $-114.2M | $-68.5M | $-51.7M | $-30.9M | $-22.2M |
| Income Tax Expense | $152.0K | $-4.8M | $1.5M | $-1.5M | $-1.7M | $-724.0K | $-254.0K | $-396.0K |
| Net Income | $-219.0M | $-169.0M | $-180.7M | $-112.7M | $-66.8M | $-51.0M | $-30.6M | $-21.8M |
| Net Margin | -301.7% | -479.2% | -669.7% | -779.3% | -571.2% | -491.0% | -221.8% | -306.1% |
| EPS (Basic) | $-3.16 | $-2.90 | $-5.08 | $-3.80 | $-2.67 | $-2.66 | $-2.77 | $-49.78 |
| EPS (Diluted) | $-3.16 | $-2.90 | $-5.08 | $-3.80 | $-2.67 | $-2.66 | $-2.77 | $-49.78 |
| Shares Outstanding (Basic) | 69.3M | 58.2M | 35.6M | 29.7M | 25.1M | 19.1M | 11.0M | 814.7K |
| Shares Outstanding (Diluted) | 69.3M | 58.2M | 35.6M | 29.7M | 25.1M | 19.1M | 11.0M | 814.7K |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |